PT-141 (Bremelanotide)
10mg
Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan-II but with selective MC4R activity. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide is the first centrally-acting agent for sexual desire that works through melanocortin rather than dopaminergic or serotonergic pathways. It acts in the hypothalamus and limbic system to modulate sexual arousal and desire circuits.
Pricing
Mechanism of Action
PT-141 selectively activates MC3R and MC4R in hypothalamic and limbic structures. MC4R activation in the paraventricular nucleus and medial preoptic area modulates oxytocinergic and dopaminergic neurotransmission involved in sexual arousal, desire, and genital vasocongestion. Unlike PDE5 inhibitors (which act peripherally on vascular smooth muscle), bremelanotide engages the central motivational circuitry of sexual behavior. Intranasal delivery was abandoned in clinical trials due to blood pressure effects; subcutaneous administration is the approved route.
Properties
Molecular Formula
C₅₀H₆₈N₁₄O₁₀
Molecular Weight
1025.17 Da
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Half-Life
~2.7 hours
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 21 days.
Research Applications
References & Citations
(2)The Female Sexual Response and the Melanocortin System
Kingsberg SA, Clayton AH, Pfaus JG.
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
Clayton AH, Althof SE, Kingsberg S, et al.
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.